文献速递胸部外周血管CT

个体化高螺距CT肺动脉造影有助于减少对比剂用量

Personalized high pitch CTPA facilitates a reduction of contrast agent volume.
PubMed 文献 · Eur J Radiol · 2025-05-16

前瞻性研究纳入97例疑似肺栓塞患者,研究组77例采用试验团注技术确定扫描延迟并以20 mL碘美普尔400行高螺距CTPA,回顾性对照组31例以50 mL碘美普尔400行标准团注追踪CTPA;研究组肺动脉干强化虽较低但达到诊断阈值的比例相当,对比剂用量显著减少。

要点

  • 试验团注指导的个体化高螺距CTPA可将对比剂用量从50 mL降至20 mL碘美普尔400。
  • 研究组肺动脉干平均CT值336±116 HU,仍高于200 HU诊断阈值。
  • 对照组上腔静脉强化显著更高(1241±795 HU vs 430±337 HU),提示标准方案对比剂时机可能欠佳。

核心结论

  • 试验团注技术指导的个体化高螺距CTPA可优化扫描延迟,在保持肺动脉诊断性强化的同时显著减少对比剂用量,可能对存在对比剂肾病风险的患者尤其有益。

研究设计与样本

  • 前瞻性试验(n=97)纳入疑似肺栓塞转诊行CTPA的患者,研究组n=77采用试验团注技术确定最佳扫描延迟并以20 mL碘美普尔400行高螺距CTPA,回顾性选择的对照组n=31以50 mL碘美普尔400行标准团注追踪方案,两名独立阅片者分析图像。

关键影像表现/征象

  • 研究组肺动脉干平均强化336±116 HU,对照组平均517±185 HU(p<0.001)。
  • 对照组上腔静脉平均强化1241±795 HU,研究组平均430±337 HU(p<0.001)。

诊断标准与关键数值

  • 两组达到肺动脉干诊断性强化值(>200 HU)的患者比例相当。

临床应用与阅片要点

  • 采用试验团注技术确定个体化扫描延迟,可在高螺距CTPA中以20 mL碘美普尔400获得满足诊断阈值(>200 HU)的肺动脉强化。

局限性

  • 对照组为回顾性选择。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Despite advancements in computed tomography pulmonary angiography (CTPA), optimizing contrast agent (CA) volume remains crucial due to inter-patient hemodynamic variability. This study aimed to evaluate a personalized scan delay approach using a test bolus technique to minimize CA volume while maintaining diagnostic image quality.

PATIENT AND METHODS: A prospective trial (n = 97) was conducted on patients referred for CTPA due to suspected pulmonary embolism (PE). The study group (n = 77) underwent CTPA with a reduced CA volume (20 mL Iomeron 400 i.v.) guided by a test bolus technique to determine the optimal scan delay. Standard CTPA exclusion criteria were applied; no study-related exclusion criteria were defined. A retrospectively selected control group (n = 31) underwent CTPA using a standard bolus tracking protocol with 50 mL Iomeron 400 i.v. Two independent readers performed image analysis.

RESULTS: PE was detected in 21 patients in the study group and y patients in the control group. Attenuation values in the pulmonary trunk were significantly lower in the study group (mean 336 ± 116 HU) compared to the control group (mean 517 ± 185 HU) (p < 0.001). However, a comparable proportion of patients in both groups achieved diagnostic attenuation values (>200 HU) in the pulmonary trunk. The superior vena cava (SVC) attenuation was significantly higher in the control group (mean 1241 ± 795 HU) compared to the study group (mean 430 ± 337 HU) (p < 0.001), suggesting potentially suboptimal contrast timing in the standard protocol.

CONCLUSION: Personalized high-pitch CTPA, guided by a test bolus technique, facilitates an optimized scan delay, enabling a significant reduction in contrast agent volume while preserving diagnostic attenuation of the pulmonary arteries. This approach may be particularly beneficial in patients at risk for contrast-induced nephropathy.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Varga R, Weiss F, Raudner M, et al. Personalized high pitch CTPA facilitates a reduction of contrast agent volume. Eur J Radiol. 2025. PMID: 40449459. doi:10.1016/j.ejrad.2025.112172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。